NCT00950612View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 8, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK's investigational vaccine 692342

Intramuscular injection, 2 doses

BIOLOGICAL

Placebo

Intramuscular injection, 2 doses

Trial Locations (1)

6850

GSK Investigational Site, Worcester

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Aeras
All Listed Sponsors
collaborator

Aeras

OTHER

lead

GlaxoSmithKline

INDUSTRY